Focus: Celularity is a public biotechnology company specializing in placenta-derived stem cell therapies, with a diversified pipeline spanning oncology, immunology, and regenerative medicine. The company operates as a mid-cap biotech with ~$54M in FY2025 revenue and is focused on clinical-stage cell therapy development.
Profile data last refreshed 17h ago · AI intelligence enriched 4w ago
Stable — net -2 jobs in 30d
0 added, 2 removed. Backfill posture.
Celularity offers early-stage cell therapy exposure and public-company credibility, but severe liquidity constraints and an immature pipeline make this a high-risk career move unless you have deep capital-raise or restructuring expertise.
Help build intelligence for Celularity
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Celularity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Celularity Inc. (CELU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Celularity Inc. (CELU) Stock Price, News, Quote & History Yahoo! Finance Canada
Celularity Inc. (CELU) stock price, news, quote and history - Yahoo Finance UK
Celularity Inc. (CELU) stock price, news, quote and history Yahoo Finance UK
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner - Yahoo Finance
Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner Yahoo Finance
A Bali center is expected to be the region’s first to offer stem-cell treatment from placentas. - Stock Titan
A Bali center is expected to be the region’s first to offer stem-cell treatment from placentas. Stock Titan
Celularity Q1 Results: EPS turns positive at $0.02, sales down 66% - scanx.trade
Celularity Q1 Results: EPS turns positive at $0.02, sales down 66% scanx.trade
Celularity Announces Naveen Jain to Join Board of Directors - Yahoo Finance
Celularity Announces Naveen Jain to Join Board of Directors Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo